This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Abion Inc., Seoul National University. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 20 
2 out of 1,789 
Years Active: 2022-2025
Title: Innovations of Sung Youl Hong
Introduction
Sung Youl Hong is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of three patents, his work focuses on advanced therapeutic methods and compositions.
Latest Patents
One of his latest patents is a method for treating or sensitizing interferon beta resistant cancer using cFLIP siRNA. This invention relates to a pharmaceutical composition that includes an siRNA that binds to the mRNA of the cFLIP gene, along with a human interferon beta variant. Another significant patent involves an antibody that specifically binds to ECL-2 of claudin 3. This invention is aimed at cancer cell detection, diagnosis, imaging, and treatment applications, showcasing the potential of antibodies in anticancer therapies.
Career Highlights
Sung Youl Hong has worked with prominent organizations such as Abion Inc. and Seoul National University. His experience in these institutions has contributed to his expertise in the field of cancer research and treatment.
Collaborations
He has collaborated with notable colleagues, including Young Kee Shin and Jun Young Choi, further enhancing his research and development efforts.
Conclusion
Sung Youl Hong's innovative work in cancer treatment through his patents demonstrates his commitment to advancing medical science. His contributions are paving the way for new therapeutic approaches in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile